Belite Bio, Inc BLTE
Annual
Quarterly
No annual revenue total was found in Belite Bio, Inc's SEC filings.
Belite Bio, Inc (BLTE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$37.1 million. As of Dec 31, 2025 it held $352.9 million in cash and investments and $429,000 in total debt.
Revenue
—
Net income
$-77.61M
-114.7% vs prior year
Operating cash flow
$-36.99M
-26.5% vs prior year
Free cash flow
$-37.06M
-26.3% vs prior year
EPS
$-2.31
-95.8% vs prior year
Dividend per share
None
Shares outstanding
39.34M
+23.6% vs prior year
Net cash
$352.50M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BLTE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1889109
- Former names
- BELITE BIO, INC (until Oct 30, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$84.2M | -$40.0M | -$31.7M | -$12.8M |
| Net income | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| Diluted EPS | -$2.31 | -$1.18 | -$1.19 | -$0.63 |
| Operating cash flow | -$37.0M | -$29.2M | -$29.8M | -$11.5M |
| Free cash flow | -$37.1M | -$29.4M | -$29.9M | -$11.9M |
| Total assets | $780.6M | $152.1M | $94.6M | $44.3M |
| Total liabilities | $10.1M | $6.3M | $4.2M | $2.8M |
| Stockholders' equity | $770.5M | $145.8M | $90.4M | $41.5M |
| Cash and investments | $352.9M | $36.2M | $88.2M | $42.1M |
| Total debt | $429,000 | $537,000 | $886,000 | $866,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 12, 2026 |
| 6-K | Current report (foreign issuer) | Aug 11, 2026 | Aug 11, 2026 |
| 6-K | Current report (foreign issuer) | Jun 15, 2026 | Jun 12, 2026 |
| 6-K | Current report (foreign issuer) | May 20, 2026 | May 20, 2026 |
All 214 Belite Bio, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.